Go to content

Newsroom

Lastest news

Follow the latest from Medicago

May 282019
Press Release
ATUM Licenses Exclusive Access to Proprietary Gene-Coding Algorithm for Plant-Based Recombinant Protein Expression to Medicago
April 252019
Press Release
Medicago Awarded “Best New Vaccine Technology/Platform” at the World Vaccine Congress
March 202019
Media Article
Congratulations Nathalie Landry as a finalist for the Mercuriades 2019 in the category Leadership, Outstanding Woman Sun Life Financial
March 72019
Media Article
Best New Vaccine Technology/platform Award Finalist
January 152019
Media Article
ViE Awards 2019 Nominees & Voting
January 102019
Media Article
Québec, an innovative city
December 202018
Media Article
Canadian Biotech Breaking New Ground in the Fight Against Infectious Disease
October 302018
Media Article
Life sciences - Québec International
September 272018
Media Article
Return of U.S. Flu Season Brings Worries About a Virulent Replay (Bloomberg)
September 242018
Media Article
Plant-Derived VLPs as a Novel Approach to Addressing an Unmet Need in Influenza Prevention
September 182018
Press Release
Medicago officially starts the construction of its site in Estimauville's Innovation Area
September 262017
Press Release
Medicago Announces Phase 3 Study of VLP Quadrivalent Influenza Vaccine
March 62017
Press Release
Medicago's Board of Directors asked company CEO Andy Sheldon to explore new business opportunities for Medicago.
March 12018
Media Article
This Company Is Testing a Flu Vaccine Made In Tobacco -- And Philip Morris Is On Board (Forbes)
October 292015
Press Release
Medicago engaged by the canadian government to develop ebola monoclonal antibodies.
May 192015
Press Release
Medicago to build $245m production facility in Quebec city

ATUM Licenses Exclusive Access to Proprietary Gene-Coding Algorithm for Plant-Based Recombinant Protein Expression to Medicago

NEWARK, Calif., & QUEBEC CITY--(BUSINESS WIRE)--ATUM, a Newark, California-based leader in the development of protein expression technologies, announced today the exclusive licensing of gene-coding algorithm GeneGPS® to optimize protein expression in Nicotiana benthamiana to Medicago, a global leader in the development and production of plant-derived vaccines and therapeutic proteins. The gene design technology was developed using ATUM’s patented gene optimization algorithm that combines design of experiments (DoE), exact empirical measurements, and machine learning tools to accurately predict the preferred gene sequence.

ATUM announced the exclusive licensing of its gene-coding algorithm GeneGPS® to optimize protein expression in Nicotiana benthamiana to Medicago.

“The ATUM GeneGPS technology has continuously demonstrated robust and predictable protein expression in our Proficia® plant-based manufacturing platform,” said Marc-André D’Aoust, Ph.D., Vice President, Research & Innovation at Medicago. “Combining our proprietary transient protein expression technologies with the GeneGPS algorithm results in unprecedented productivity in the generation of VLP vaccine and antibody candidates.”

Claes Gustafsson, Ph.D., Chief Commercial Officer and Co-Founder of ATUM, added: “The impressive and unique technology platform put in place by Medicago to quickly provide vaccines through plant-based protein production provides a new exciting tool to improve human health. We are pleased to have worked with Medicago to reach their goals by developing and licensing to them exclusive access to the proprietary Nicotiana benthamiana gene design GeneGPS platform.”

About GeneGPS®

ATUM’s patented GeneGPS® technology eliminates bias, incorrect assumptions, and flawed optimization strategies in gene design by focusing on what has been experimentally demonstrated to improve expression. GeneGPS® begins with a training set of systematically varied synthetic gene variants, whose expression is experimentally tested in a target host. The expression data is analyzed using machine learning to develop a gene design algorithm for that host. Genes designed using GeneGPS® reliably outperform genes designed using alternative methods.

ATUM has built GeneGPS® optimization algorithms for many bacterial, yeast, insect, plant, fungal, and mammalian expression hosts, and continues to improve and develop GeneGPS® for novel expression hosts.

About Medicago

Medicago is a Canadian clinical-stage biopharmaceutical company with more than 400 employees in Canada and the United States. Medicago’s mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global health challenges. For more information: http://www.medicago.com

About ATUM

ATUM offers an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors, and platforms for protein and cellular engineering and production. The company exploits the dependence of biological activity on well-designed sequences. ATUM’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. By collaborating with our clients, ATUM accelerates breakthroughs and moves research further faster. For more information please visit: https://www.atum.bio.

Medicago Awarded “Best New Vaccine Technology/Platform” at the World Vaccine Congress

Medicago Awarded “Best New Vaccine Technology/Platform” at the World Vaccine Congress

Washington, D.C., USA, April 25, 2019 – Medicago, a North American biotech company and global leader in the development and production of plant-derived vaccines, announced today that its proprietary plant-based production platform, Proficia® was named “Best New Vaccine Technology/platform” at the World Vaccine Congress in Washington, D.C., attended by 1,500 participants including key opinion leaders from the vaccine industry. The Vaccine Industry Excellence (ViE) Awards recognize the outstanding achievements of vaccine practitioners and stakeholders across the global vaccine industry.


“It is very gratifying to see that our technology is again being recognized as innovative in our industry”, said Bruce Clark, President & Chief Executive Officer of Medicago. “Winning this award as the best new technology in the eyes of leading experts in the vaccine industry is an important validation of the value of our plant-based technology to vaccine and antibody development.”


Developed in Quebec City, Medicago’s technology has the potential to rapidly respond to surging threats by producing vaccines or therapeutic antibodies in the face of an outbreak such as pandemic influenza. Our data has shown that the Proficia® platform can:

  • Rapidly deliver a pandemic vaccine candidate in 5 to 6 weeks
  • Accurately match the selected strain as a result of its recombinant technology
  • Easily scale vaccine production as one plant or 10,000 plants require the same growth conditions

Medicago’s platform versatility has been demonstrated for the production of vaccines and antibodies. In 2012, in the context of DARPA’s Blue Angel program, the company successfully proved its platform capacity to produce 10 million doses of a candidate H1N1 pandemic vaccine in one month at its state-of-the-art manufacturing plant in North Carolina. Medicago’s influenza development program includes a pandemic, a seasonal and a universal flu vaccine. In addition to flu vaccines, in 2015, Medicago successfully completed a contract with the U.S. government (BARDA) to produce anti-Ebola antibodies.

On top of this newly received award, Medicago’s platform Proficia® was awarded the “Game-changing Technology Award in 2014, by BIOTECanada”. This prize recognized an organization that had made a significant contribution to the biotech industry in Canada through the innovative plant-based vaccine production platform.


In 2018, Medicago broke ground on the new $245 million manufacturing complex in Quebec City that will include the company's headquarters, research and development as well as production facilities. The new production factory will complement the one of Durham, North Carolina as the company plans to produce annually 40 to 50 million doses of quadrivalent vaccines against seasonal influenza. In 2019, Medicago will achieve a key milestone by completing Phase III clinical studies in adults and elderly subjects.


About World Vaccine Congress
The World Vaccine Congress remains the industry's definitive vaccine industry event for major vaccine players. Officially the longest-running and largest vaccine industry event in North America, the World Vaccine Congress delivers a forum where the ever-changing dynamics of the vaccine industry are discussed and acted upon by the industry's most senior figures.


About Medicago
Medicago is a Canadian clinical-stage biopharmaceutical company with more than 450 employees in Canada and the United States. Medicago’s mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global health challenges. 
 

Congratulations Nathalie Landry as a finalist for the Mercuriades 2019 in the category Leadership, Outstanding Woman Sun Life Financial

Leadership, Femme d’exception Financière Sun Life
Ce Mercure vise à reconnaître le parcours exceptionnel d’une femme d’affaires ayant fait preuve d’audace, d’influence et de leadership tout au long de son parcours professionnel et au sein de son secteur d’activité.

PME

Danielle Danault, présidente, Cardio Plein Air
Marie-Claude Beauchamp, présidente et productrice, Carpediem Film & TV
Marion Duchesne, fondatrice et présidente, Mediaclip
Nathalie Landry, vice-présidente exécutive, Affaires médicales et scientifiques, Medicago
GRANDE ENTREPRISE

Diane Lemieux, présidente-directrice générale, Commission de la construction du Québec (CCQ)
Sylvie Tardif, Vice-présidente aux opérations et logistique, Groupe BMR
Lynne Roiter, présidente et chef de la direction, Loto-Québec
Nathalie Lehoux, présidente, Restaurants Pacini

Best New Vaccine Technology/platform Award Finalist

We are delighted to announce that our Plant-based Vaccine Production Platform, Proficia, has been shortlisted for the ViE Awards in the category: Best New Vaccine Technology/platform Award.
The Winners will be announced at the 12th ViE Awards Ceremony & Gala Dinner in Washington, DC, on April 15th. #Medicago #staytuned #WVCUSA

ViE Awards 2019 Nominees & Voting

Québec, an innovative city

Canadian Biotech Breaking New Ground in the Fight Against Infectious Disease

Life sciences - Québec International

Return of U.S. Flu Season Brings Worries About a Virulent Replay (Bloomberg)

Plant-Derived VLPs as a Novel Approach to Addressing an Unmet Need in Influenza Prevention

Medicago officially starts the construction of its site in Estimauville's Innovation Area

Medicago Announces Phase 3 Study of VLP Quadrivalent Influenza Vaccine

Medicago's Board of Directors asked company CEO Andy Sheldon to explore new business opportunities for Medicago.

This Company Is Testing a Flu Vaccine Made In Tobacco -- And Philip Morris Is On Board (Forbes)

Medicago engaged by the canadian government to develop ebola monoclonal antibodies.

Medicago to build $245m production facility in Quebec city

Media Contact
|
Paméla Champagne-Côté
TACT Intelligence-conseil
| Media enquiries

Want to be the first to know about Medicago news?

Sign up for our newsletter.

Scientific
publications

Transforming the approach
to vaccines and therapeutic proteins

Here are the current published studies and contributions from Medicago's scientists and researchers.

June 5, 2019
Immunogenicity and safety of a quadrivalent plant-derived virus-like particle influenza vaccine candidate—Two randomized Phase II clinical trials in 18 to 49 and 50 years old adults
Authors: Stéphane Pillet, Julie Couillard, Sonia Trépanier, Jean-François Poulin, Bader Yassine-Diab, Bruno Guy, Brian J. Ward, Nathalie Landry
May 15, 2019 Vaccine
Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages
Authors: Makarkov, Makan Golizeh, Elizabeth Ruiz-Lancheros, Angelica A. Gopal, Ian N. Costas-Cancelas, Sabrina Chierzi, Stephane Pillet, Nathalie Charland, Nathalie Landry, Isabelle Rouiller, Paul W. Wiseman, Momar Ndao, and Brian J. Ward
October 31, 2018 Vaccine
Characterization of the innate stimulatory capacity of plant-derived virus-like particles bearing influenza hemagglutinin
Authors: So-Yoon Wona, Kristin Hunt, Hannah Guak, Benedeta Hasaj, Nathalie Charland, Nathalie Landry, Brian J. WardConnie M. Krawczyk
October 31, 2018
Investigation of an Adventitious Agent Test False Positive Signal in a Plant-Derived Influenza Vaccine
Authors: Todd L. Talarico, Michael Murphy, Raymond Nims, Dan Hastings, Jeri Ann Boose, and Dave Dumers
September 12, 2018
The adjuvant GLA-AF enhances human intradermal vaccine responses
Authors: Darrick Carter, Neal van Hoeven, Susan Baldwin, Yotam Levin, Efrat Kochba, Al Magill, Nathalie Charland, Nathalie Landry, Khin Nu, Aude Frevol, Jill Ashman, Zachary K. Sagawa, Anna Marie Beckmann, Steven G. Reed
April 24, 2018 Vaccine
Assessing the benefits of early pandemic influenza vaccine availability: a case study for Ontario, Canada
Authors: David Champredon, Marek Laskowski, Nathalie Charland & Seyed M. Moghadas
February 23, 2018 Vaccine
Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy.
Authors: Lindsay BJ, Bonar MM, Costas-Cancelas IN, Hunt K, Makarkov AI, Chierzi S, Krawczyk CM, Landry N, Ward BJ, Rouiller I.
January 16, 2018 Human Vaccines & Immunotherapeutics
The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?
Authors: Ward BJ, Pillet S, Charland N, Trepanier S, Couillard J, Landry N.
October 11, 2017 Vaccine
A single intramuscular dose of a plant-made virus-like-particle vaccine elicits a balanced humoral and cellular response and protects young and aged mice from influenza H1N1 challenge 4despite a modest/absent humoral response
Authors: Breanna Hodgins, Karen K Yam, Kaitlin Winter, Stephane Pillet, Nathalie Landry and Brian J. Ward
July 2, 2017 Vaccine
Plant-made virus-like particles bearing influenza hemagglutinin (HA) recapitulate early interactions of native influenza virions with human monocytes/macrophages.
Authors: Makarkov AI, Chierzi S, Pillet S, Murai KK, Landry N, Ward BJ
May 2, 2017 Human Vaccines & Immunotherapeutics
Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro.
Authors: Hendin HE, Pillet S, Lara AN, Wu CY, Charland N, Landry N, Ward BJ.
March 16, 2017 Vaccine
Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro
Authors: Hilary E. Hendin, Stéphane Pillet, Amanda N. Lara, Cheng-Ying Wua, Nathalie Charland, Nathalie Landry, Brian J. Ward
July 24, 2016 Vaccine
Cell wall biochemical alterations during Agrobacterium-mediated expression of haemagglutinin-based influenza virus-like vaccine particles in tobacco
Authors: Franccois Le Mauff, Corinne Loutelier-Bourhis, Muriel Bardor, Caroline Berard, Alain Doucet, Marc-André D'Aoust, Louis-Philippe Vezina, Azeddine Driouich, Manon M.-J. Couture and Patrice Lerouge
October 2, 2015 Vaccine
Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets
Authors: S. Pillet, T. Racine, C. Nfond, T.Z. Di Lenardob, S. Babiukd, B.J. Ward, G.P. Kobingerc, N. Landry
June 2, 2015
Generation and characterization of a trackable plant-made influenza H5 virus-like particle (VLP) containing enhanced green fluorescent protein (eGFP)
Authors: Katie R. Young, Guillaume Arthus-Cartier, Karen K. Yam, Pierre-Olivier Lavoie, Nathalie Landry, Marc-André D'Aoust, Louis-Philippe Vézina, Manon M.-J. Couture, and Brian J. Ward
April 21, 2015
Modulating secretory pathway pH by proton channel co-expression can increase recombinant protein stability in plants
Authors: Philippe V. Jutras, Marc-André D'Aoust, Manon M.-J. Couture, Louis-Philippe Vézina, Marie-Claire Goulet, Dominique Michaud, Frank Sainsbury
September 19, 2014
Human antibody response to N-glycans present on plant-madeinfluenza virus-like particle (VLP) vaccines
Authors: Brian J. Ward, Nathalie Landry, Sonia Trépanier, Geneviève Mercier,Michèle Dargis, Manon Couture, Marc-André D'Aoust, Louis-P. Vézinab
August 14, 2014
Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens
Authors: Nathalie Landry, Stéphane Pillet, David Favre, Jean-François Poulin, Sonia Trépanier, Bader Yassine-Diab, Brian J. Ward